Basic safety assessments indicated that gastrointestinal adverse events, mostly nausea and diarrhea, were dose-dependent but normally mild and transient. These conclusions set up the therapeutic window and knowledgeable dose range for subsequent Stage three trials.Renal elimination of unchanged orforglipron is minimal, with excretion taking place m